Life Sciences Patents

ACI’s 21st Advanced Summit on Life Sciences Patents returns to New York City, this May, to provide practical insights on how to maximize your patent term and develop strategies to enhance global protections for your patent portfolio.

Effectively and strategically prosecuting patents is critical to business. In the face of district court litigations, inter-partes review and post-grant proceedings, a granted patent, no matter its content and history, remains vulnerable to attack. Therefore, learning how to better prepare patent portfolios by keeping future litigation concerns in mind at the prosecution stage is mission critical and our faculty of global thought leaders will help you develop forward-thinking strategies through our sophisticated and practical workshops and panels.

The carefully crafted modules will help attendees navigate international developments in life sciences patent law as they impact your global patent prosecution strategy, from the new Unitary Patent and Unified Patent Court in Europe, Safe Harbor exemptions around the world, or the role of AI as an inventor.

Equally, as we enter an era of increased biotech innovation and transformation, this advanced summit will help you examine recent life sciences IP controversies and patent rights with new technologies such as mRNA, CAR T and CRISPR. Securing IP rights to these technologies and leveraging or licensing these rights appropriately is essential to successful commercialization, growth, and future development of these innovations.

This May, join the “who’s who” of the global pharmaceutical, biotech and medtech industries as they gather in person for ACI’s 21st Advanced Summit on Life Sciences Patents, and learn how to thrive in increasingly challenging and globalized times.

Attend and engage in face-to-face discussions with leading stakeholders on best practices for filing and defending patent portfolios, including:

• Establishing sound and successful protocols to procure and enforce life sciences patents in the U.S. and internationally
• Developing new standards of drafting successful genus claims in anticipation of the U.S. Supreme Court review of enablement in Amgen v. Sanofi
• Evaluating the “pros and cons” of opting-into the EU’s new Unitary Patent system and the Unified Patent Court for your global pharmaceutical patent portfolio
• Bullet-proofing your patent portfolio against skinny labelling claims and safe harbor exemptions
• Obtaining and enforcing patent rights for novel therapeutics and gene therapies